HomeCompareGRPH vs PLD

GRPH vs PLD: Dividend Comparison 2026

GRPH yields 64.78% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.68M in total portfolio value· pulled ahead in Year 9
10 years
GRPH
GRPH
● Live price
64.78%
Share price
$3.18
Annual div
$2.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$821.3K
Annual income
$203,467.89
Full GRPH calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — GRPH vs PLD

📍 PLD pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRPHPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRPH + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRPH pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRPH
Annual income on $10K today (after 15% tax)
$5,506.29/yr
After 10yr DRIP, annual income (after tax)
$172,947.71/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,295,023.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRPH + PLD for your $10,000?

GRPH: 50%PLD: 50%
100% PLD50/50100% GRPH
Portfolio after 10yr
$3.66M
Annual income
$2,729,952.04/yr
Blended yield
74.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

GRPH
Analyst Ratings
7
Hold
1
Sell
Consensus: Hold
Price Target
$4.00
+25.8% upside vs current
Range: $2.00 — $7.00
Altman Z
5.3
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRPH buys
0
PLD buys
0
No recent congressional trades found for GRPH or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRPHPLD
Forward yield64.78%3.18%
Annual dividend / share$2.06$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$821.3K$6.50M
Annual income after 10y$203,467.89$5,256,436.18
Total dividends collected$690.7K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$4.00$136.00

Year-by-year: GRPH vs PLD ($10,000, DRIP)

YearGRPH PortfolioGRPH Income/yrPLD PortfolioPLD Income/yrGap
1$17,178$6,477.99$11,255$555.24+$5.9KGRPH
2$28,780$10,399.89$13,062$1,018.59+$15.7KGRPH
3$47,079$16,284.27$15,903$1,926.67+$31.2KGRPH
4$75,270$24,895.34$20,839$3,823.32+$54.4KGRPH
5$117,738$37,198.68$30,464$8,166.08+$87.3KGRPH
6$180,359$54,379.70$52,054$19,457.30+$128.3KGRPH
7$270,837$77,853.00$109,886$54,188.93+$161.0KGRPH
8$399,056$109,260.19$304,030$186,451.18+$95.0KGRPH
9← crossover$577,444$150,453.99$1,166,125$840,813.32$588.7KPLD
10$821,333$203,467.89$6,504,190$5,256,436.18$5.68MPLD

GRPH vs PLD: Complete Analysis 2026

GRPHStock

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Full GRPH Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this GRPH vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRPH vs SCHDGRPH vs JEPIGRPH vs OGRPH vs KOGRPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.